Note: ∗ represents the primary outcome measure, which determines the overall quality of the article; ⊕ represents the ranking of quality as high, ⊕⊕ represents the ranking of quality as moderate, ⊕⊕⊕ represents the ranking of quality as low, and ⊕⊕⊕⊕ represents the ranking of quality as very low. (1) Risk of Bias: the included study has large biases in terms of randomization, allocation concealment, blinding, and loss of follow-up. (2) Inconsistency: the overlapping of confidence intervals of different studies is poor, and the I2 value of the combined results is large. (3) Indirectness: differences in populations, interventions, and outcomes. (4) Imprecision: the sample size of the included studies was too small and the confidence interval was wide. (5) Publication bias: funnel diagram shows asymmetry, gray literature was not retrieved and the search database is incomplete.Outcomes: (1) total efficiency: according to the severity of clinical symptoms using 4 scores; the total score is the sum of the individual scores. Symptom Score Reducing Index (SSRI) = (total score before treatment-total score after treatment)/total score before treatment×100%; (2) adverse reaction rate; (3) recurrence rate; (4) clinical efficacy rate: the clinical complete recovery is considered to be effective, others are invalid; (5) improvement rate; (6) curing rate; (7) IgE levels; (8) the Dermatology Quality Life Index (DLQI); (9) quality of life score (QoL); (10) total improvement of clinical signs and symptoms; (11) disease activity control.
